Some of the most expensive drugs in the country are derived from biotechnology. But there is no law or regulatory pathway at the Food and Drug Administration to allow for cheaper biotech drugs such as those derived from chemicals like cholesterol pills or arthritis tablets with which doctors and their patients have become so familiar. Kathleen Jaeger, president and chief executive officer of the Generic Pharmaceutical Association tells the Chicago Tribune's Bruce Japsen about the state of the debate over a pathway for cheaper generic biotech drugs.
